Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SRDX's Cash to Debt is ranked higher than
95% of the 294 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. SRDX: No Debt )
SRDX' s 10-Year Cash to Debt Range
Min: 50.6   Max: No Debt
Current: No Debt

Equity to Asset 0.94
SRDX's Equity to Asset is ranked higher than
99% of the 279 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. SRDX: 0.94 )
SRDX' s 10-Year Equity to Asset Range
Min: 0.74   Max: 0.96
Current: 0.94

0.74
0.96
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
98% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 178.70 vs. SRDX: No Debt )
SRDX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 39.94
M-Score: -3.02
WACC vs ROIC
12.62%
22.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 33.38
SRDX's Operating margin (%) is ranked higher than
99% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.96 vs. SRDX: 33.38 )
SRDX' s 10-Year Operating margin (%) Range
Min: -20.11   Max: 51.75
Current: 33.38

-20.11
51.75
Net-margin (%) 20.80
SRDX's Net-margin (%) is ranked higher than
98% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.43 vs. SRDX: 20.80 )
SRDX' s 10-Year Net-margin (%) Range
Min: -35.08   Max: 32.59
Current: 20.8

-35.08
32.59
ROE (%) 13.21
SRDX's ROE (%) is ranked higher than
88% of the 272 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. SRDX: 13.21 )
SRDX' s 10-Year ROE (%) Range
Min: -12.91   Max: 23.9
Current: 13.21

-12.91
23.9
ROA (%) 12.43
SRDX's ROA (%) is ranked higher than
94% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. SRDX: 12.43 )
SRDX' s 10-Year ROA (%) Range
Min: -11.85   Max: 19.94
Current: 12.43

-11.85
19.94
ROC (Joel Greenblatt) (%) 105.51
SRDX's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 294 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. SRDX: 105.51 )
SRDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18.72   Max: 154.38
Current: 105.51

-18.72
154.38
Revenue Growth (3Y)(%) 11.10
SRDX's Revenue Growth (3Y)(%) is ranked higher than
86% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. SRDX: 11.10 )
SRDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -24.6   Max: 57.8
Current: 11.1

-24.6
57.8
EBITDA Growth (3Y)(%) 12.70
SRDX's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.70 vs. SRDX: 12.70 )
SRDX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.6   Max: 92.2
Current: 12.7

-32.6
92.2
EPS Growth (3Y)(%) 11.80
SRDX's EPS Growth (3Y)(%) is ranked higher than
86% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. SRDX: 11.80 )
SRDX' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.4   Max: 46.8
Current: 11.8

-35.4
46.8
» SRDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SRDX Guru Trades in Q1 2014

Mario Gabelli 33,300 sh (+113.23%)
Jim Simons 510,395 sh (+12.14%)
Chuck Royce 733,300 sh (unchged)
Joel Greenblatt Sold Out
Bill Frels 739,540 sh (-0.82%)
» More
Q2 2014

SRDX Guru Trades in Q2 2014

Mario Gabelli 130,778 sh (+292.73%)
Chuck Royce 744,800 sh (+1.57%)
Bill Frels 738,470 sh (-0.14%)
Jim Simons 504,238 sh (-1.21%)
» More
Q3 2014

SRDX Guru Trades in Q3 2014

Mario Gabelli 185,398 sh (+41.77%)
Chuck Royce 744,800 sh (unchged)
Jim Simons 501,938 sh (-0.46%)
Bill Frels 728,390 sh (-1.36%)
» More
Q4 2014

SRDX Guru Trades in Q4 2014

Jim Simons 582,738 sh (+16.10%)
Bill Frels Sold Out
Chuck Royce 718,400 sh (-3.54%)
Chuck Royce 718,400 sh (-3.54%)
Mario Gabelli 120,398 sh (-35.06%)
Bill Frels 40,790 sh (-94.40%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.70
SRDX's P/E(ttm) is ranked higher than
83% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 29.70 )
SRDX' s 10-Year P/E(ttm) Range
Min: 8.5   Max: 687.94
Current: 29.7

8.5
687.94
Forward P/E 26.95
SRDX's Forward P/E is ranked higher than
77% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 26.95 )
N/A
PE(NRI) 29.80
SRDX's PE(NRI) is ranked higher than
89% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 29.80 )
SRDX' s 10-Year PE(NRI) Range
Min: 8.52   Max: 668.29
Current: 29.8

8.52
668.29
P/B 4.10
SRDX's P/B is ranked higher than
59% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. SRDX: 4.10 )
SRDX' s 10-Year P/B Range
Min: 0.98   Max: 7.77
Current: 4.1

0.98
7.77
P/S 6.30
SRDX's P/S is ranked lower than
51% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.66 vs. SRDX: 6.30 )
SRDX' s 10-Year P/S Range
Min: 2.16   Max: 13.8
Current: 6.3

2.16
13.8
PFCF 20.70
SRDX's PFCF is ranked higher than
91% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 20.70 )
SRDX' s 10-Year PFCF Range
Min: 8.44   Max: 511.5
Current: 20.7

8.44
511.5
POCF 18.61
SRDX's POCF is ranked higher than
88% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 18.61 )
SRDX' s 10-Year POCF Range
Min: 5.96   Max: 36.68
Current: 18.61

5.96
36.68
EV-to-EBIT 16.45
SRDX's EV-to-EBIT is ranked higher than
92% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 16.45 )
SRDX' s 10-Year EV-to-EBIT Range
Min: -47.4   Max: 253.6
Current: 16.45

-47.4
253.6
Shiller P/E 155.10
SRDX's Shiller P/E is ranked higher than
73% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 155.10 )
SRDX' s 10-Year Shiller P/E Range
Min: 16.62   Max: 160.5
Current: 155.1

16.62
160.5
Current Ratio 11.03
SRDX's Current Ratio is ranked higher than
97% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. SRDX: 11.03 )
SRDX' s 10-Year Current Ratio Range
Min: 1.57   Max: 18.27
Current: 11.03

1.57
18.27
Quick Ratio 10.23
SRDX's Quick Ratio is ranked higher than
97% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. SRDX: 10.23 )
SRDX' s 10-Year Quick Ratio Range
Min: 1.49   Max: 18
Current: 10.23

1.49
18
Days Inventory 130.39
SRDX's Days Inventory is ranked higher than
70% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 141.40 vs. SRDX: 130.39 )
SRDX' s 10-Year Days Inventory Range
Min: 33.96   Max: 234.64
Current: 130.39

33.96
234.64
Days Sales Outstanding 28.07
SRDX's Days Sales Outstanding is ranked higher than
96% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 81.46 vs. SRDX: 28.07 )
SRDX' s 10-Year Days Sales Outstanding Range
Min: 28.08   Max: 80.51
Current: 28.07

28.08
80.51

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.40
SRDX's Price/Net Cash is ranked higher than
86% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 13.40 )
SRDX' s 10-Year Price/Net Cash Range
Min: 3.9   Max: 700
Current: 13.4

3.9
700
Price/Net Current Asset Value 11.30
SRDX's Price/Net Current Asset Value is ranked higher than
82% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 11.30 )
SRDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.27   Max: 160.14
Current: 11.3

3.27
160.14
Price/Tangible Book 4.80
SRDX's Price/Tangible Book is ranked higher than
78% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.80 vs. SRDX: 4.80 )
SRDX' s 10-Year Price/Tangible Book Range
Min: 1.26   Max: 18.49
Current: 4.8

1.26
18.49
Price/DCF (Projected) 1.90
SRDX's Price/DCF (Projected) is ranked higher than
89% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 1.90 )
SRDX' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 4.59
Current: 1.9

0.53
4.59
Price/Median PS Value 1.00
SRDX's Price/Median PS Value is ranked higher than
85% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. SRDX: 1.00 )
SRDX' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 7.76
Current: 1

0.4
7.76
Price/Peter Lynch Fair Value 7.50
SRDX's Price/Peter Lynch Fair Value is ranked higher than
87% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 7.50 )
SRDX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.47   Max: 31.8
Current: 7.5

0.47
31.8
Price/Graham Number 2.40
SRDX's Price/Graham Number is ranked higher than
90% of the 332 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 2.40 )
SRDX' s 10-Year Price/Graham Number Range
Min: 0.9   Max: 12.63
Current: 2.4

0.9
12.63
Earnings Yield (Greenblatt) 6.30
SRDX's Earnings Yield (Greenblatt) is ranked higher than
90% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. SRDX: 6.30 )
SRDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 22
Current: 6.3

0.4
22
Forward Rate of Return (Yacktman) 21.95
SRDX's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. SRDX: 21.95 )
SRDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.1   Max: 52.9
Current: 21.95

1.1
52.9

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 59 61 71
EPS($) 0.94 1.00 1.18
EPS without NRI($) 0.94 1.00 1.18

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
SurModics, Inc. was organized as a Minnesota corporation in June 1979. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company's core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. It partners with many of the emerging medical device, pharmaceutical and life science companies to develop and commercialize innovative products designed to improve patient outcomes. Although its drug delivery and surface modification technologies themselves are not directly regulated by the Food and Drug Administration, the medical devices, pharmaceutical and biotechnology products incorporating its technologies are subject to FDA regulation.
» More Articles for SRDX

Headlines

Articles On GuruFocus.com
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 12 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 10 2009 
SurModics Reports First Quarter 2009 Results Jan 28 2009 
SurModics to Webcast Fiscal 2009 First Quarter Earnings Conference Call January 28 Jan 14 2009 


More From Other Websites
Baxter Files New Drug Application for BAX 855 in Japan - Analyst Blog Apr 17 2015
Thoratec's HeartMate II Scores High in ENDURANCE Trial - Analyst Blog Apr 17 2015
Baxter Amends Financial Provisions of Coherus Collaboration - Analyst Blog Apr 16 2015
Omeros' OMS721 Available in Europe for Compassionate Use - Analyst Blog Apr 15 2015
Puma Biotechnology Expands Study Cohort for Cancer Drug - Analyst Blog Apr 15 2015
GW Pharmaceuticals (GWPH) Jumps: Stock Rises 13.1% - Tale of the Tape Apr 15 2015
Cerner, Qualcomm to Enhance Home Healthcare - Analyst Blog Apr 14 2015
athenahealth to Boost Health Management at Trinity Health - Analyst Blog Apr 14 2015
Medtronic, IBM Health Unit Tie Up for Diabetes Management - Analyst Blog Apr 14 2015
NuVasive Poised on Balanced Growth, International Expansion - Analyst Blog Apr 14 2015
Zimmer (ZMH) Extends Biomet Deal Outside Date to Jul 23 - Analyst Blog Apr 14 2015
Allscripts' CCM Program Adopted by CFP Physicians Group - Analyst Blog Apr 14 2015
Akers' Distribution Deals Expand International Footprint - Analyst Blog Apr 14 2015
Quality Systems Unveils Health Care Platform, Buys Gennius - Analyst Blog Apr 13 2015
3 Big-Volume Stocks Triggering Breakout Trades Apr 13 2015
Walgreens Boots to Close 200 Drugstores in US, Shares Up - Analyst Blog Apr 10 2015
Cerner's HealtheLife App to be Available on Apple Watch - Analyst Blog Apr 10 2015
Ecolab's 3D TRASAR CIP Program Named Product of the Year - Analyst Blog Apr 09 2015
Walgreens Boots (WBA) Tops Q2 Earnings, Revenues Lag - Analyst Blog Apr 09 2015
Cerner Teams Up to Start 'Aging in Place' Community Program - Analyst Blog Apr 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK